A Phase 1/2 Study of HST-1011 Immunotherapy in People With Solid Tumors

Full Title

An Open Label, Phase 1/2 Study of HST-1011 Given as Monotherapy and in Combination with an Anti-PD1 Antibody in Patients with Advanced Solid Tumors

Purpose

The purpose of this study is to find the best dose of HST-1011 for people with advanced solid tumors. The people in this study have cancer that spread (metastasized) and keeps growing even after getting treatment.

HST-1011 may boost your immune system to help your body fight cancer. It does this by attaching to a specific protein. HST-1011 is taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

• Have a metastatic solid tumor that keeps growing after treatment.
• Have finished prior chemotherapy at least 3 weeks before getting HST-1011 (2 weeks since radiation therapy).
• Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Claire Friedman’s office at 646-888-4247.